In some embodiments provided herein is a method of treating pain, the method comprising administering into the subject

a pharmaceutical composition comprising multivesicular liposomes encapsulating bupivacaine phosphate, said multivesicular liposomes comprising

bupivacaine or a salt thereof;

phosphoric acid;

a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group; and,

optionally, a cholesterol and/or a plant sterol wherein said multivesicular liposomes are made by a process comprising:

a) preparing a first aqueous component comprising phosphoric acid;

b) preparing a lipid component comprising at least one organic solvent, at least one amphipathic lipid, and at least one neutral lipid lacking a hydrophilic head group;

c) mixing said first aqueous component and said lipid component to form a water-in-oil emulsion, wherein at least one component comprises bupivacaine or a salt thereof;

d) mixing said water-in-oil emulsion with a second aqueous component to form solvent spherules; and

e) removing the organic solvent from the solvent spherules to form multivesicular liposomes encapsulating bupivacaine phosphate,

wherein inadvertent administration of the pharmaceutical composition into the vasculature of the subject does not result in cardiac side effects or CNS side effects in the subject.

A method of producing a composition for a treatment of cardiovascular and cerebrovascular diseases is provided. The method includes the following steps of: a) according to a ratio of 1 lt, adding 2 ml 36.5-37.5% formic aldehyde solution to 998 ml sterile and 0.85-0.95% isotonic sodium chloride solution to obtain a mixture, mixing the mixture thoroughly and obtaining an aldehyde solution with a final concentration of 0.073-0.075% by weight for injection, and b) storing the composition obtained in a dark place at a temperature of 15-35° C.

A method of producing a composition for a treatment of cardiovascular and cerebrovascular diseases is provided. The method includes the following steps of: a) according to a ratio of 1 lt, adding 2 ml 36.5-37.5% formic aldehyde solution to 998 ml sterile and 0.85-0.95% isotonic sodium chloride solution to obtain a mixture, mixing the mixture thoroughly and obtaining an aldehyde solution with a final concentration of 0.073-0.075% by weight for injection, and b) storing the composition obtained in a dark place at a temperature of 15-35° C.

Disclosed are niclosamide formulations for use as antiviral therapy. The formulations disclosed herein may be used for treating a sexually-transmitted virus or a respiratory virus (e.g., coronavirus).

Disclosed are niclosamide formulations for use as antiviral therapy. The formulations disclosed herein may be used for treating a sexually-transmitted virus or a respiratory virus (e.g., coronavirus).

A method of producing an osteoinductive composition for in vivo use, in which the method includes obtaining bone tissue; cleaning the bone tissue with a plurality of washes; milling, grinding, and/or cutting the cleaned bone tissue into a plurality of bone pieces or fibers of a desired size; and demineralizing the plurality of bone pieces or fibers of a desired size to expose one or more native bone proteins, with demineralizing including combining the plurality of bone pieces or fibers in a reaction vessel with an ionic acid solution, soaking the plurality of bone pieces or fibers in the ionic acid solution, and exposing the one or more native proteins in the bone pieces or fibers.

A method of producing an osteoinductive composition for in vivo use, in which the method includes obtaining bone tissue; cleaning the bone tissue with a plurality of washes; milling, grinding, and/or cutting the cleaned bone tissue into a plurality of bone pieces or fibers of a desired size; and demineralizing the plurality of bone pieces or fibers of a desired size to expose one or more native bone proteins, with demineralizing including combining the plurality of bone pieces or fibers in a reaction vessel with an ionic acid solution, soaking the plurality of bone pieces or fibers in the ionic acid solution, and exposing the one or more native proteins in the bone pieces or fibers.

Described is an aqueous calcium gluconate solution formulated without calcium saccharate, which can be stored in a flexible plastic bag and can be terminally sterilized.

Described is an aqueous calcium gluconate solution formulated without calcium saccharate, which can be stored in a flexible plastic bag and can be terminally sterilized.

The present disclosure provides a compositions and methods of inhibiting O.sup.6-methylguanine DNA methyltransferase in human tumor cells by providing an effective amount of an agent that directly or indirectly inhibits the O.sup.6-methylguanine DNA methyltransferase in a pharmaceutically acceptable carrier, wherein the amount is effective to potentiate an anti-tumor activity of one or more alkylating agents, platinum drugs, or antimetabolites, wherein tumor cells are triggered into programmed cell death.